GU Cancers 2023 | The rationale of the ROAR trial

Kamal Sahu, MBBS, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, explains the rationale of the ROAR trial (NCT03533946) which investigated rucaparib for patients with non-metastatic hormone sensitive prostate cancer who have a ‘BRCAness’ genotype. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.